Ha Tay Pharmaceutical JSC (HNX:DHT)
Vietnam · Delayed Price · Currency is VND 49,900
+1,000 (2.04%)
At close: Nov 3, 2026
Ha Tay Pharmaceutical JSC Financials Overview
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 2,381,679 | 2,402,040 | 2,086,353 | 1,999,304 | 1,837,395 | 1,609,364 |
Revenue Growth | 5.78% | 15.13% | 4.35% | 8.81% | 14.17% | -19.79% |
Gross Profit Gross Profit Growth | 188,007 | 209,189 | 219,818 | 203,331 | 187,256 | 154,022 |
Operating Income Operating Income Growth | 11,998 | 40,711 | 76,513 | 99,216 | 102,450 | 62,070 |
Net Income Net Income Growth | 33,974 | 53,657 | 71,772 | 85,056 | 95,211 | 67,946 |
Earnings Per Share EPS Growth | - | 586.46 | 720.37 | 1390.07 | 1064.19 | 765.31 |
EPS Growth | - | -18.59% | -48.18% | 30.62% | 39.05% | -25.61% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 217,662 | 234,337 | 180,270 | 381,790 | 152,931 | 422,483 |
Total Debt Total Debt Growth | 243,633 | 333,064 | 470,187 | 503,700 | 336,844 | 289,429 |
Net Cash (Debt) Net Cash Growth | -25,971 | -98,727 | -289,917 | -121,910 | -183,912 | 133,054 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | - | -1079.07 | -2909.89 | -1992.39 | -2055.62 | 1498.67 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 153,691 | 225,719 | 27,959 | 270,799 | -39,471 | -23,293 |
Capital Expenditures CapEx Growth | -24,977 | -48,759 | -143,132 | -366,523 | -246,553 | -60,524 |
Free Cash Flow Free Cash Flow Growth | 128,714 | 176,961 | -115,173 | -95,725 | -286,024 | -83,817 |
Free Cash Flow Growth | 160.20% | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 7.89% | 8.71% | 10.54% | 10.17% | 10.19% | 9.57% |
Operating Margin | 0.50% | 1.70% | 3.67% | 4.96% | 5.58% | 3.86% |
Pretax Margin | 2.05% | 3.05% | 4.56% | 5.52% | 6.71% | 5.56% |
Profit Margin | 1.43% | 2.23% | 3.44% | 4.25% | 5.18% | 4.22% |
FCF Margin | 5.40% | 7.37% | -5.52% | -4.79% | -15.57% | -5.21% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 3, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 826.446 | - | - | - | 295.159 | 295.159 |
Dividend Per Share Growth | - | - | - | - | 0% | - |
Dividend Yield | 1.66% | - | - | - | 2.57% | 2.22% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 3, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 143.40 | 118.16 | 108.99 | 22.27 | 10.79 | 17.49 |
P/FCF Ratio | 37.85 | 35.83 | - | - | - | - |
PS Ratio | 2.05 | 2.64 | 3.75 | 0.95 | 0.56 | 0.74 |